Form 4: Recursion Pharmaceuticals Director Blake Borgeson Sells Shares Under 10b5-1 Plan

Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals (RXRX) at an average price of $9.5052 under a pre-arranged 10b5-1 trading plan.

Summary

• On June 25, 2024, Blake Borgeson, a director at Recursion Pharmaceuticals, sold 11,447 shares of Class A Common Stock.
• The sale was executed at a weighted average price of $9.5052, with individual trades ranging from $9.325 to $9.82.
• The transaction was conducted under a Rule 10b5-1 trading plan adopted on August 18, 2023.
• Following the transaction, Borgeson directly owns 7,177,116 shares of Recursion Pharmaceuticals.
• Jonathan Golightly, attorney-in-fact, signed the Form 4 on June 27, 2024.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to an insider share sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment, as these sales are often planned for personal financial management.

Industry Context

Insider sales are a common occurrence, and sales under 10b5-1 plans are often pre-scheduled to avoid accusations of trading on inside information. The market typically views these sales in the context of the overall financial health and future prospects of the company.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates